Advanced search
Publication Cover
Cancer Biology & Therapy Volume 19, 2018 - Issue 4
Submit an article Journal homepage
1,322
Views
4
CrossRef citations to date
0
Altmetric
Research Paper

Remarkable response with pembrolizumab plus albumin-bound paclitaxel in 2 cases of HER2-positive metastatic breast cancer who have failed to multi-anti-HER2 targeted therapy

Bian LiDepartment of Breast Cancer, Chinese PLA 307 Hospital, Beijing, ChinaView further author information
,
Wang TaoDepartment of Breast Cancer, Chinese PLA 307 Hospital, Beijing, ChinaView further author information
,
Zhang Shao-huaDepartment of Breast Cancer, Chinese PLA 307 Hospital, Beijing, ChinaView further author information
,
Qu Ze-ruiDepartment of Breast Cancer, Chinese PLA 307 Hospital, Beijing, ChinaView further author information
,
Jin Fu-quanDepartment of Breast Cancer, Chinese PLA 307 Hospital, Beijing, ChinaView further author information
,
Li FanDepartment of Breast Cancer, Chinese PLA 307 Hospital, Beijing, ChinaView further author information
&
Jiang Ze-feiDepartment of Breast Cancer, Chinese PLA 307 Hospital, Beijing, ChinaCorrespondence[email protected]
View further author information
 show all
Pages 292-295 | Received 15 Aug 2017, Accepted 05 Dec 2017, Published online: 18 Jan 2018

References

  • Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32. doi:10.3322/caac.21338.
  • Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer:correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177–82. doi:10.1126/science.3798106.
  • Diéras V, Miles D, Verma S, Pegram M, Welslau M, Baselga J, Krop IE, Blackwell K, Hoersch S, Xu J, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(6):732–742. doi:10.1016/S1470-2045(17)30312-1.
  • Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733–43. doi:10.1056/NEJMoa064320.
  • von Minckwitz G, Schwedler K, Schmidt M, Barinoff J, Mundhenke C, Cufer T, Maartense E, de Jongh FE, Baumann KH, Bischoff J, et al. Trastuzumab beyond progression:overall survival analysis of the GBG 26/BIG 3–05 phase III study in HER2-positive breast cancer. Eur J Cancer. 2011;47(15):2273–81. doi:10.1016/j.ejca.2011.06.021.
  • Dong Y, Sun Q, Zhang X. PD-1 and its ligands are important immune checkpoints in cancer. Oncotarget. 2017;8(2):2171–2186. doi:10.18632/oncotarget.13895.
  • Muenst S, Soysal SD, Gao F, Obermann EC, Oertli D, Gillanders WE. The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer.Breast Cancer Res Treat. 2013;139(3):667–76. doi:10.1007/s10549-013-2581-3.
  • Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res. 2015;3(5):436–43. doi:10.1158/2326-6066.CIR-15-0064.
  • Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016;17(11):1497–1508. doi:10.1016/S1470-2045(16)30498-3.
  • Wang T, Zhou J, Zhang S, Bian L, Hu H, Xu C, Hao X, Liu B, Ye Q, Liu Y, et al. Meaningful interpretation of serum HER2 ECD levels requires clear patient clinical background, and serves several functions in the efficient management of breast cancer patients.Clin Chim Acta. 2016;458:23–9. doi:10.1016/j.cca.2016.04.025.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.